Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
In this real-world cohort of patients with MPM treated with ipi-nivo survival outcomes were inferior to those reported in the CheckMate-743 and MAPS2 trials, whereas safety outcomes were similar.
Authors
- Lorenz Frehner
- Kira‐Lee Koster (ORCID: https://orcid.org/0000-0002-6549-8124)
- Sacha I. Rothschild (ORCID: https://orcid.org/0000-0003-1304-9340)
- Katrin Gysel
- Lisa Holer
- Laura Boos (ORCID: https://orcid.org/0000-0002-4287-799X)
- Christine Waibel
- Anna Allemann
- Martin Früh (ORCID: https://orcid.org/0000-0002-4047-1734)
- Michael Mark
- Christian Britschgi (ORCID: https://orcid.org/0000-0001-8831-1564)
- Sabine Cardoso Almeida
- Yannis Metaxas (ORCID: https://orcid.org/0000-0001-5290-9660)
- Patrizia Froesch (ORCID: https://orcid.org/0000-0002-8140-1249)
- Sabine Schmid (ORCID: https://orcid.org/0000-0003-0840-3253)
- Laetitia Mauti (ORCID: https://orcid.org/0000-0002-6652-1947)
- Wolf-Dieter Janthur (ORCID: https://orcid.org/0009-0005-4139-2260)
- Catherine Von der Mühll-Schill
Institutions
- University of Bern (CH)
- University of Lucerne (CH)
- Kantonsspital St. Gallen (CH)
- University Hospital of Bern (CH)
- University Hospital of Basel (CH)
- Ente Ospedaliero Cantonale (CH)
- Kantonsspital Winterthur (CH)
- University Hospital of Zurich (CH)
- Kantonsspital Münsterlingen (CH)
- Kantonsspital Baden (CH)
- St. Claraspital (CH)
- Swiss Group For Clinical Cancer Research (CH)
- Kantonsspital Aarau (CH)
- Università della Svizzera italiana (CH)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100735
- Citations
- 6
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.51